Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (539)	2/15/2000 2:08:00 PM
From: tuck	Respond to of 586

Jeffrey, Given the amazing volume these past few days, I don't think we're going to notice if insiders were to sell now. An interesting chunk from CYPB's latest quarterly tells me dilution is coming down the pike unless these guys get cash flow positive quickly: sec.gov Note the number of shares out is given as 46 million and change. Note further that the number authorized is 60 million for th common. They've just had an exercise of 7 million by the CEO. Doesn't that come from the treasury stock, thus adding 7 million to the shares outstanding? So they could only issue 7 million more shares without a vote. The preferred has been retired, but I believe they are authorized to issue 3.33333 million shares of that. What does this mean in the overall context of CYPB recent past and near future stock price? It means that whatever is causing this pump, it will be over when they announce more stock placements, probably private placements of the convertible preferred. They'd have to issue a lot of good news to counteract that. I don't see the PROSORBA column being very widely used, but if it can keep the company afloat without further dilution, then we have upside from CYPB's platelet research, long term. We could see news on PII trials for the platelet transfusion product in the next few weeks /months. In that scenario, the stock could well deserve middle single digits. OK, so then after preferred is issued, a vote gets on the ballot for the next shareholders meeting to increase the number of authorized shares. By the time the deal goes off, the price should have bottomed for 'em and they load up once again. These up and down with dilution scenarios depend on the company not making money for a while. Isn't that supposed to be the case for about a year? Do we have any clue as to when earnings are coming out? Gotta dig for that and a couple of other things. If I can't call the number of the top, maybe I can call the time, which would be even better. Right now, FWIW, Thompson I-Watch shows about 20% institutional and 10% other, with rest being retail. HMMMMMM. Cheers, Tuck

To: BRAVEHEART who wrote (539)	2/17/2000 3:19:00 PM
From: tuck	Read Replies (1) \| Respond to of 586

Jeffrey, Some resistance at $4. But CYPB is churning through it on good volume. The chart shows momentum enough to carry it through $4 soon, in my HO. And then I just don't know, but at least $5. I may cash out part of the position if that happens. siliconinvestor.com Jeffrey, if Aries and Paramount have been drying up the float, where is all this volume coming from? Thompson I-Watch shows only 20% institutional volume today. OK, so the mo' players/day traders are here. That means when the volume tapers, I'll be selling, unless convinced otherwise. Cheers, Tuck